Avutometinib (VS-6766)

About Verastem Oncology

Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.

Therapeutic Areas